E-Therapeutics (LON:ETX) has hired a pharma and biotech veteran to bolster its focus on commericialising its most promising compounds.
Professor Trevor Mervyn Jones CBE, 73, becomes a non-exec director, the AIM firm told investors.
Meanwhile, director Dr Rajesh Chopra, has resigned to return to a full-time academic research career.
Chief executive of e-Therapeutics, Professor Malcolm Young, said: "Professor Jones' exceptional research and development experience and illustrious record will be an immensely valuable addition to the team as we ramp up towards realising the commercial potential of our discovery and development assets.
"I would also like to thank Raj Chopra on behalf of e-Therapeutics for his long and considerable contributions to the company and we all wish him well in the next stage of his career.
"The appointment of Professor Jones further supports our new primary focus on commercialising our most promising compounds and programmes."
Jones has over 40 years' distinguished experience in the pharmaceutical and biotech industry as well as in academia. He is the visiting professor at King's College, London and holds honorary degrees from seven universities.
He is currently chairman at contract research organisation Simbec-Orion Group and Welsh investment company, Arthurian Life Sciences.
He was a member of the UK Government Pharmaceutical Industry Ministerial Strategy Working Group on Pharmaceuticals and adviser to the Cabinet Office on the Human Genome Project in 2001.
The group's discovery platform currently has 10 live projects, which will be whittled down for formal pre-clinical development early next year, with the most promising to enter clinical development in 2017.
Currently, there is a phase IIb clinical stage drug candidate for major depressive disorder, ETS6103; and a phase Ib clinical stage candidate in hepatocellular and pancreatic cancer, ETS2101.